Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MAXZIDE is a fixed-dose combination oral tablet containing hydrochlorothiazide (a thiazide diuretic) and triamterene (a potassium-sparing diuretic) approved in 1984. It is indicated for hypertension management, combining two complementary mechanisms to reduce blood pressure while minimizing potassium depletion. The drug works by increasing urinary sodium and water excretion while conserving potassium, making it a balanced diuretic therapy.
As LOE approaches, the brand team is likely consolidating; expect headcount reductions and a shift toward defensive positioning against generics.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MAXZIDE in 2024 is a defensive, operational role focused on managed decline and generic transition rather than growth or innovation. Career development is limited; this assignment is best suited for professionals managing mature portfolios or those seeking operational/supply-chain expertise rather than commercial or clinical advancement.
Worked on MAXZIDE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.